Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

PartnershipCNSidePositive

AI Analysis

Summary

Plus Therapeutics secured a regional coverage agreement with Medical Mutual for its CNSide cerebrospinal fluid assay, expanding coverage to approximately 1.2 million people in Ohio and Kentucky and bringing total contracted coverage to approximately 127 million people.

Outcome Details

Regional coverage agreement secured

Importance:5/10

Sentiment:

0.60

coverage agreementinsurancediagnostic assayCNS cancermarket expansion

Related Companies

$MDCE

Read the original article

Published by GlobeNewswire Pharma on July 21, 2026 11:30 AM

Read Original